Avalo Therapeutics, Inc.

The company is a clinical-stage biotechnology firm that develops therapies targeting interleukin-1β for immune-mediated inflammatory diseases. Its primary product candidate is abdakibart, a humanized monoclonal antibody designed to block interleukin-1β and inhibit downstream inflammatory pathways. The candidate targets adults with moderate to severe hidradenitis suppurativa, a debilitating chronic skin condition. The firm also maintains legacy programs across other inflammatory and mitochondrial disorders. As its candidates remain in clinical evaluation without regulatory approvals, the company currently engages clinical study participants, with future customers comprising patients who suffer from underserved inflammatory diseases.

The enterprise conducts clinical operations across thirteen countries, including the United States, Canada, France, Germany, Italy, Spain, Bulgaria, the Czech Republic, Greece, Poland, Australia, Turkey, and Slovakia. Its primary Phase 2 trial encompasses approximately 250 adult participants. The business owns no manufacturing facilities, relying on external contract development and manufacturing organizations to produce its biologic supplies. The provided text does not state the location of the corporate headquarters.

Summary of the business section of Avalo Therapeutics's latest annual report, written by StockData.

“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.

“As of December 31, 2024, we had twenty-three employees, all of whom were full-time.”